Cardiff Oncology Inc (TROV)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

11055 FLINTKOTE AVENUE SAN DIEGO, CA 92121

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company's prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive 'Lazarus Spallanzani') in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L.
TrovaGene is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Co.'s tests predominantly use transrenal deoxyribonucleic acid and transrenal ribonucleic acid. Co.'s technology uses urine collection and can be applied to a range of testing including: prenatal genetic testing, infectious diseases, tumor detection and monitoring, tissue transplantation, forensic identification and for patient selection in clinical trials.

Data as of 2020-11-22
Market Cap643.614 Million Shares Outstanding35.325 Million Avg 30-day Volume864.294 Thousand
P/E Ratio-12.1 Dividend Yield EPS-1.51
Price/Sales1896.81 Price cash flow ratio Price free cash flow ratio-44.3
Book Value0.95 Price to Tangible Book19.2 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.033569
BETA1.50848 52-week High/Low18.97 / 0.701 Stddev0.346952
View SEC Filings from TROV instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 5 1 400.0% 2 (0.13%) 0 (0.0%)
Funds Holding: 66 32 106.25% 20 (1.31%) 9 (0.58%) 122.22%
13F shares: 18.554 Million 4.924 Million 276.83% 8.521 Million 2.557 Million 233.3%
% Ownership 74.2172 24.6581 200.99% 34.0847 12.8036 166.21%
New Positions: 42 15 180.0% 15 6 150.0%
Increased Positions 11 7 57.14% 4 2 100.0%
Closed Positions 5 5 0.0% 3 1 200.0%
Reduced Positions 6 3 100.0% 1
Total Calls 522.029 Thousand 0 72.817 Thousand
Total Puts 219.999 Thousand 0 60.187 Thousand
PUT/CALL Ratio 0.42 0.83
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

 
Cardiff Oncology Inc Chart by YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

WhaleWisdom Alpha

Our Other Reporting & Analysis

Funds Holding TROV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TROV BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

35.3 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

35.3 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KELEMEN VICKI EXEC. VP AND COO

  • Officer
 5,054 2020-11-23 2

RA CAPITAL MANAGEMENT, L.P.

KOLCHINSKY PETER

SHAH RAJEEV M.

  • 10% Owner
 3,290,000 2020-09-30 1

PACE GARY W

  • Director
 450,311 2020-09-16 5

BRANCACCIO JOHN P

  • Director
 0 2020-06-17 2

ADAMS THOMAS PHD EXECUTIVE CHAIRMAN

  • Officer
  • Director
 0 2020-06-17 2

JACOB GARY S

  • Director
 0 2020-06-17 2

MARKIN RODNEY S

  • Director
 0 2020-06-17 2

ERLANDER MARK CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 0 2020-06-17 4

ARMITAGE JAMES O

  • Director
 0 2020-06-17 4

WHITE LALE

  • Director
 0 2020-06-17 4

COUNTOURIOTIS ATHENA

  • Director
 0 2019-06-20 0

TENNANT STANLEY

  • Director
 28,839 2018-06-08 0

WELCH WILLIAM J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 842,645 2018-01-30 0

BILLINGS PAUL

  • Director
 0 2018-01-23 0

BRIDGER MANAGEMENT, LLC

MIGNONE ROBERTO

  • 10% Owner
  • FORMER 10% OWNER
No longer subject to file 2016-11-11 0

ZANIBONI STEVE FORMER CFO

  • Officer
 96,968 2016-04-21 0

SCHUH ANTONIUS CEO

  • Officer
  • Director
 0 2016-01-04 0

POSARD MATTHEW L. CHIEF COMMERCIAL OFFICER

  • Officer
 0 2016-01-04 0

FELDBAUM CARL B

  • Director
 0 2015-03-17 0

CERRONE GABRIEL

  • FORMER DIRECTOR
 0 2013-07-26 0

MCGUIGAN CHRISTOPHER

  • Director
 0 2013-02-14 0

HUNTER ROBERT MERRILL

  • 10% Owner
 5,065,004 2012-04-13 0

SHEINERMAN KIRA

  • Director
 909,090 2008-06-12 0

POLIAKOFF ABBA DAVID

  • Director
 0 2008-01-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KELEMEN VICKI - Officer EXEC. VP AND COO

2020-11-25 16:02:46 -0500 2020-11-23 M 35,321 $2.48 a 40,375 direct 12.7281 12.7281 2 0.0 1

KELEMEN VICKI - Officer EXEC. VP AND COO

2020-11-25 16:02:46 -0500 2020-11-23 M 35,321 $2.48 d 70,641 direct

KELEMEN VICKI - Officer EXEC. VP AND COO

2020-11-25 16:02:46 -0500 2020-11-23 S 35,321 $18.60 d 5,054 direct 12.7281 12.7281 2 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments